Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, ...

By Maggie Fick and Lucy Raitano LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify ...

April 14 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.

Trump previously floated a 25% tariff on all imported drugs, though they were unaffected by recent reciprocal levies.

Novo Nordisk got the go-ahead for its once-daily ... and has also been given a green light in Australia, Japan, Switzerland, and the EU. Both are vying for market share with Roche's near $5 ...

Novo Nordisk's anti-TFPI antibody concizumab has ... including Japan, Australia, and Switzerland, but was rejected by the FDA last year with a request for more information related to the ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time ...

Switzerland's Roche and France's Sanofi dropped 5.7% and 6.4% respectively in Europe. Japan's Daiichi Sankyo and Takeda Pharmaceutical closed 6% and 4.7% lower, respectively. The drug sector was ...

Column chart showing Novo Nordisk shares monthly percentage change ... fund manager at healthcare-focused Bellevue Asset Management in Switzerland, which holds Novo shares, said he and other ...